Daniel J. Siegwart is a Professor in the Department of Biomedical Engineering, Department of Biochemistry, and the Simmons Comprehensive Cancer Center (SCCC) at the University of Texas Southwestern Medical Center. He holds the W. Ray Wallace Distinguished Chair in Molecular Oncology Research and serves as the Director of the Program in Genetic Drug Engineering, Director of the Drug Delivery Program in Biomedical Engineering, and Co-leader of the Chemistry and Cancer Program in the NCI-designated SCCC. He received a BS in Biochemistry from Lehigh University (2003), and a PhD in Chemistry from Carnegie Mellon University (2008), studying with Professor Krzysztof Matyjaszewski. He also studied as an NSF EAPSI Research Fellow at the University of Tokyo with Professor Kazunori Kataoka (2006). He then completed an NIH NSRA Postdoctoral Fellowship at MIT with Professor Daniel Anderson and Professor Robert Langer (2008-2012). Among various honors and awards, he has been elected to Controlled Release Society (CRS) College of Fellows and the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. His research laboratory utilizes materials chemistry to enable targeted nanoparticle delivery of genomic medicines. Their efforts led to an understanding of the essential physical and chemical properties of synthetic carriers required for therapeutic delivery of siRNA, miRNA, tRNA, pDNA, mRNA, and gene editors. His lab has been at the forefront in the design of synthetic carriers for gene editing, reporting the first example of non-viral in vivo CRISPR/Cas gene editing, and has applied these technologies for correction of genetic diseases and treatment of cancer. He also developed Selective ORgan Targeting (SORT) lipid nanoparticles (LNPs) for predictable tissue specific mRNA delivery and gene editing. Dr. Siegwart and his lab ultimately aspire to utilize chemistry and engineering to make a beneficial impact on human health.